二甲苯嗪相关创面的外科处理:回顾性分析与流程建议
该研究回顾了美国东北部某学术中心2018至2023年间66例会诊的二甲苯嗪相关创面,发现创面可遍布全身,多伴慢性化与感染;继续注射与愈合不良相关,戒断注射者愈合率更高;作者据此提出多学科分期重建流程。
要点
- 二甲苯嗪相关创面可遍布全身,常为慢性且合并感染。
- 继续注射者愈合率低,戒断注射与愈合相关。
- 慢性非感染创面可先行局部创面处理,优化后分期重建。
核心结论
- 二甲苯嗪相关创面可发生于全身各部位,物质使用康复与愈合相关;慢性非感染创面局部处理有效,患者优化后宜分期重建,多学科流程有助于标准化诊疗。
研究设计与样本
- 回顾性研究,纳入2018至2023年美国东北部某学术中心66例因二甲苯嗪相关创面行整形与骨科外科会诊的住院患者,经IRB豁免后经Epic系统检索病历。
- 分类变量采用Fisher精确检验,显著性设定为P<0.05,并制定治疗流程。
主要发现
- 创面部位:手臂/前臂54.5%、下肢47.0%、手33.3%、颈7.6%、胸3.0%、腹1.5%。
- 69.7%为慢性创面(>3个月),20.0%伴骨外露。
- 65.2%伴急性感染:蜂窝织炎47.0%、骨髓炎24.2%、脓肿22.7%、脓毒症9.1%;1例(1.5%)为坏死性软组织感染(NSTI)并急诊清创。
- 治疗方式:仅局部创面处理45.5%、仅手术清创22.7%、皮肤移植19.7%、皮肤替代物10.6%、局部组织重排3.0%、游离皮瓣3.0%、截肢9.1%。
- 随访:72.7%初次治疗后继续注射,13.6%停止注射,13.6%失访;研究结束时25.8%创面完全愈合,27.3%部分愈合。
临床怎么用
- 对慢性非感染性二甲苯嗪相关创面可先行局部创面处理。
- 伴感染或骨外露者需评估清创,患者优化后采用分期重建策略。
- 应将物质使用康复纳入多学科管理以改善愈合。
局限性
- 单中心回顾性研究,样本量66例,部分亚组样本小。
- 13.6%患者失访,愈合结局可能受影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Xylazine is a veterinary sedative that is added to illicit fentanyl to prolong its euphoric effects. When injected subcutaneously, xylazine causes large, necrotic wounds. In 2023, the White House designated fentanyl adulterated with xylazine as an emerging US public health threat. To date, the optimal surgical management of xylazine-associated wounds is not well understood. METHODS: A total of 66 inpatient plastic and orthopedic surgery consultations for xylazine-associated wounds at an academic center in the northeast United States between 2018 and 2023 were reviewed. Following IRB exemption, charts were identified through report generation in Epic Systems. Categorical variables were compared using Fisher's exact test with significance set at P < 0.05. A treatment algorithm was developed. RESULTS: Wounds were located on the arm/forearm (54.5%), lower extremity (47.0%), hand (33.3%), neck (7.6%), chest (3.0%), and abdomen (1.5%). 69.7% presented with a chronic wound (>3 months). 20.0% presented with exposed bone. 65.2% presented with acute infection: 47.0% cellulitis, 24.2% osteomyelitis, 22.7% abscess, and 9.1% sepsis. One patient (1.5%) presented with an NSTI and was debrided urgently. Management included local wound care alone (45.5%), surgical debridement alone (22.7%), skin grafting (19.7%), skin substitute (10.6%), local tissue rearrangement (3.0%), free flap (3.0%), and amputation (9.1%). 72.7% continued to inject after initial treatment, 13.6% stopped injecting, and 13.6% were lost to follow-up. By study completion, 25.8% fully healed their wound, and 27.3% partially healed. 13.0% (3/23) of patients treated with wound care fully healed, compared to 21.4% (3/14) of those treated with debridement alone ( P = 0.65). Among those who continued to inject, 20.4% (9/44) fully healed, compared to 75.0% (6/8) of those who stopped injecting ( P = 0.005). Reconstructive procedures were successful in 50% (7/14). CONCLUSIONS: Xylazine-associated wounds occur on all parts of the body. Substance use rehabilitation is associated with healing. Local wound care is effective for chronic, noninfected wounds. A staged reconstructive approach is preferred once the patient is optimized. An algorithm for multidisciplinary management is beneficial for standardizing care.
引用
- Makhoul AT, Morales CZ, Card EB, et al. Surgical Management of Xylazine-Associated Wounds: A Retrospective Review and Algorithmic Approach. Ann Plast Surg. 2026. PMID: 41490101. doi:10.1097/SAP.0000000000004616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。